Cargando…

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies

BACKGROUND AND AIMS: Treatment pathways for ulcerative colitis (UC) and Crohn’s disease (CD) are shifting to a more individualized, risk-stratified approach. The perception is that insurance policies may not have implemented this paradigm shift, particularly regarding access to newer agents. We eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dulai, Parambir S., Osterman, Mark T., Lasch, Karen, Cao, Charlie, Riaz, Faisal, Sandborn, William J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704097/ https://www.ncbi.nlm.nih.gov/pubmed/30923985 http://dx.doi.org/10.1007/s10620-019-05594-7

Ejemplares similares

Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis
por: Sandborn, William J, et al.
Publicado: (2019)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Systematic review: Safety of balloon assisted enteroscopy in Crohn’s disease
por: Arulanandan, Ahilan, et al.
Publicado: (2016)

Stool multi-omics for the study of host–microbe interactions in inflammatory bowel disease
por: Sauceda, Consuelo, et al.
Publicado: (2022)

Early Intervention With Vedolizumab and Longer-term Surgery Rates in Crohn’s Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programmes
por: Dulai, Parambir S, et al.
Publicado: (2020)

Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease
por: Moustafa, Ahmed, et al.
Publicado: (2018)

Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience
por: Shen, Bo, et al.
Publicado: (2019)

Development of Inflammatory Bowel Disease in HIV Patients: A Danish Cohort Study (1983–2018) With American Validation (1999–2018)
por: Elmahdi, Rahma, et al.
Publicado: (2022)

Breadth and Exclusivity of Hospital and Physician Networks in US Insurance Markets
por: Graves, John A., et al.
Publicado: (2020)

Access to Care, Cost of Care, and Satisfaction With Care Among Adults With Private and Public Health Insurance in the US
por: Wray, Charlie M., et al.
Publicado: (2021)

Biologic Concentration Testing in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2015)

Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn’s Disease
por: Dulai, Parambir S, et al.
Publicado: (2022)

The impact of US policy on contraceptive access: a policy analysis
por: Swan, Laura E. T.
Publicado: (2021)

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Affordability and Access Challenges Among US Subscribers to Nongroup Insurance Plans
por: Galbraith, Alison A., et al.
Publicado: (2022)

Economic policy uncertainty and directors and officers liability insurance: a perspective on capital market pressures
por: Xie, Huobao, et al.
Publicado: (2023)

US Farm households: joint decision making and impact of health insurance on labor market outcomes
por: Bharadwaj, Latika, et al.
Publicado: (2013)

U.S. Healthcare Insurance Market Concentration from 2001 to 2016: Increased Growth in Direct Written Premiums and Overall Decreased Market Consolidation
por: Ng, Mitchell K, et al.
Publicado: (2020)

Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes
por: Koliani-Pace, Jenna L, et al.
Publicado: (2019)

Economic policy uncertainty and the US stock market trading: non-ARDL evidence
por: Javaheri, Bakhtiar, et al.
Publicado: (2022)

Very high and low residual spenders in private health insurance markets: Germany, The Netherlands and the U.S. Marketplaces
por: McGuire, Thomas G., et al.
Publicado: (2020)

Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease
por: Holmer, Ariela K., et al.
Publicado: (2020)

Access to artesunate-amodiaquine, quinine and other anti-malarials: policy and markets in Burundi
por: Amuasi, John H, et al.
Publicado: (2011)

Patients’ access to rare neuromuscular disease therapies varies across US private insurers
por: Margaretos, Nikoletta M., et al.
Publicado: (2022)

Increasing Access to Farmers Markets for Beneficiaries of Nutrition Assistance: Evaluation of the Farmers Market Access Project
por: Cole, Kate, et al.
Publicado: (2013)

Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity
por: Fang, Xin, et al.
Publicado: (2020)

A developmental insurance policy
por: Saiz, Nestor, et al.
Publicado: (2017)

Access to Medicines, Access to Markets
por: Sismondo, Sergio
Publicado: (2020)

Switching costs in competitive health insurance markets: The role of insurers' pricing strategies
por: Lamiraud, Karine, et al.
Publicado: (2020)

Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES
por: Boland, Brigid S., et al.
Publicado: (2022)

Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases
por: Singh, Siddharth, et al.
Publicado: (2021)

Insurance Type Influences Access to Biologics and Healthcare Utilization in Pediatric Crohn’s Disease
por: Quiros, Jose Antonio, et al.
Publicado: (2021)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Infliximab Pricing in International Economic Evaluations in Inflammatory Bowel Disease to Inform Biologic and Biosimilar Access Policies: A Systematic Review
por: Bashir, Naazish S., et al.
Publicado: (2023)

Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US
por: Sandhaus, Robert, et al.
Publicado: (2020)

Barriers to Voting and Access to Health Insurance Among US Adults: A Cross-Sectional Study
por: Pabayo, Roman, et al.
Publicado: (2021)

Market structure and hospital–insurer bargaining in the Netherlands
por: Halbersma, R. S., et al.
Publicado: (2010)

Pricing in commercial dental insurance and provider markets
por: Nasseh, Kamyar, et al.
Publicado: (2020)

Accuracy of convolutional neural network-based artificial intelligence in diagnosis of gastrointestinal lesions based on endoscopic images: A systematic review and meta-analysis
por: Mohan, Babu P., et al.
Publicado: (2020)

White bagging, brown bagging and site of service policies: best practices in addressing provider markup in the commercial insurance market
por: Pearson, Caroline, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ujjdje6v3291nrk3splv1lrmrb